GSK 0660是一种强效的PPARβ拮抗剂，IC50值为155nM。
Cas No.:1014691-61-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GSK 0660 is a potent PPARβ antagonist with an IC50 value of 155nM [1]. GSK 0660 can prevent pathological angiogenesis and tubular structure formation by inhibiting the activity of PPARβ [2]. GSK 0660 has been widely used to regulate the activation of P38 MAPK and stimulate the migration of corneal epithelial cells[3].
In vitro, GSK 0660 treatment (5µM) for 24 hours led to a decrease in the viability of cholesteatoma Keratinocytes, inhibition of PDK1 expression, and a reduction in the phosphorylation levels of AKT and GSK3β[4]. 0.2µM of GSK 0660 treatment for 24 hours significantly inhibited 6-hydroxydopamine (6-OHDA)-induced cell death in SH-SY5Y cells, prevented oxidative stress, and increased the activity of SOD protein[5]. Treatment with 10µM GSK 0660 for 24 hours significantly reduced the expression of CCL8 and CXCL10 in human retinal microvascular endothelial cells (HRMECs) induced by TNF-α, and decreased cell adhesion[6].
In vivo, GSK 0660 treatment via daily intraperitoneal injection at a dose of 20mg/kg for 21 days significantly inhibited tumor growth and reduced tumor weight in the CT-26 xenograft mouse model[7]. Daily intraperitoneal injection of a 1mg/kg dose of GSK 0660 for 7 days can eliminate the effects of central injection of leptin on the body weight and food intake of rats, and significantly increase the serum insulin level[8].
References:
[1] Shearer B G, Steger D J, Way J M, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist[J]. Molecular endocrinology, 2008, 22(2): 523-529.
[2] Savage S R, Capozzi M E, McCollum G W, et al. The effects of pharmacologic manipulation of Peroxisome Proliferator-Activated Receptor β/on pathological angiogenesis[J]. Investigative Ophthalmology & Visual Science, 2012, 53(14): 2997-2997.
[3] Zhang Z, Pan Z, Zhang F, et al. Pparß Antagonist Mediates Increases in Human Corneal Epithelial Cell Migration Through P38 Mapk Activation[J]. Investigative Ophthalmology & Visual Science, 2010, 51(13): 1973-1973.
[4] Zhang C, Liu Y W, Chi Z, et al. Ligand‐Activated Peroxisome Proliferator‐Activated Receptor β/δ Facilitates Cell Proliferation in Human Cholesteatoma Keratinocytes[J]. PPAR research, 2020, 2020(1): 8864813.
[5] Antonosante A, Castelli V, Sette M, et al. Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson’s disease models[J]. Biological Research, 2023, 56.
[6] Capozzi M E, Savage S R, McCollum G W, et al. The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis[J]. Experimental eye research, 2020, 190: 107885.
[7] Khan B, Chen M, Wang H, et al. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression[J]. European Journal of Pharmacology, 2024, 972: 176565.
[8] Rubio B, Pintado C, Mazuecos L, et al. Central Actions of Leptin Induce an Atrophic Pattern and Improves Heart Function in Lean Normoleptinemic Rats via PPARβ/δ Activation[J]. Biomolecules, 2024, 14(8): 1028.
GSK 0660是一种强效的PPARβ拮抗剂，IC50值为155nM[1]。GSK 0660可通过抑制PPARβ的活性来阻止病理性血管生成和管状结构形成[1]。GSK 0660已被广泛用于调节P38 MAPK的激活并刺激角膜上皮细胞的迁移[3]。
在体外，5µM的GSK 0660处理胆脂瘤角质形成细胞24小时，导致细胞活力下降、PDK1表达受抑以及 AKT和GSK3β磷酸化水平降低[4]。0.2µM的GSK 0660处理SH-SY5Y细胞24小时，显著抑制了6-hydroxydopamine (6-OHDA)诱导的细胞死亡，阻止了氧化应激，并增加了SOD蛋白的活性[5]。10µM的GSK 0660处理人视网膜微血管内皮细胞(HRMECs)24小时，显著降低了TNF-α诱导的CCL8和CXCL10的表达，并减少了细胞粘附[6]。
在体内，每日腹腔注射20mg/kg剂量的GSK 0660，连续21天，显著抑制了CT-26异种移植小鼠模型中的肿瘤生长并降低了肿瘤重量[7]。每日腹腔注射1mg/kg剂量的GSK 0660，连续7天，可消除中枢注射瘦素对大鼠体重和食物摄入的影响，并显著增加血清胰岛素水平[8]。
| Cell experiment [1]: | |
Cell lines | Human Müller cells (HMCs) |
Preparation Method | HMCs were grown in DMEM with 10% (v/v) fetal bovine serum (FBS), antibiotic/antimycotic solution at 37°C in 5% CO2/atmosphere. HMCs were cultured in growth medium in 6-well dishes until approximately 70% confluent. Growth medium was aspirated and replaced with 2% FBS for 12h. HMCs were treated with fresh Palmitic acid (PA) (250µM), PA (250µM) + GSK 0660 (1µM) for 24h. The levels of inflammatory cytokines were assessed. |
Reaction Conditions | 1µM; 24h |
Applications | GSK 0660 treatment significantly inhibited PA-induced TNF-α, IL1-β, IL-6, and IL-8 in HMCs. |
| Animal experiment [2]: | |
Animal models | Male BALB/c mice |
Preparation Method | Male BALB/c mice (4 weeks old) were housed singly in a standard environment with food and water ad libitum. CT-26 cells (2×105) were injected subcutaneously into mice. Mice were treated with a control or GSK 0660 (20mg/kg/day) by intraperitoneal injection. The entire experiment lasted for 21 days. Tumor volume was measured. Tumor volume=1/2 (length×width2). |
Dosage form | 20mg/kg/day for 21 days; i.p. |
Applications | GSK 0660 treatment significantly inhibited tumor growth and reduced tumor weight in the CT-26 xenograft mouse model. |
References: | |
| Cas No. | 1014691-61-2 | SDF | |
| 化学名 | methyl 3-(N-(2-methoxy-4-(phenylamino)phenyl)sulfamoyl)thiophene-2-carboxylate | ||
| Canonical SMILES | O=S(NC(C(OC)=C1)=CC=C1NC2=CC=CC=C2)(C3=C(C(OC)=O)SC=C3)=O | ||
| 分子式 | C19H18N2O5S2 | 分子量 | 418.49 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml,DMSO: 12 mg/ml,Ethanol: 2 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3895 mL | 11.9477 mL | 23.8954 mL |
| 5 mM | 477.9 μL | 2.3895 mL | 4.7791 mL |
| 10 mM | 239 μL | 1.1948 mL | 2.3895 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet